These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 36058105)
1. Discovery of highly potent DENV NS2B-NS3 covalent inhibitors containing a phenoxymethylphenyl residue. Cheng J; Feng S; Zhang Y; Ding T; Jiang H; Zhang Z; Wang J; Wang X; Cheng M Biochem Biophys Res Commun; 2022 Oct; 627():214-219. PubMed ID: 36058105 [TBL] [Abstract][Full Text] [Related]
2. Identification and In Silico Binding Study of a Highly Potent DENV NS2B-NS3 Covalent Inhibitor. Lin X; Cheng J; Wu Y; Zhang Y; Jiang H; Wang J; Wang X; Cheng M ACS Med Chem Lett; 2022 Apr; 13(4):599-607. PubMed ID: 35450371 [TBL] [Abstract][Full Text] [Related]
3. In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease. Dwivedi VD; Tripathi IP; Mishra SK J Vector Borne Dis; 2016; 53(2):156-61. PubMed ID: 27353586 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the inhibitory potency of anti-dengue phytocompounds against DENV-2 NS2B-NS3 protease: virtual screening, ADMET profiling and molecular dynamics simulation investigations. Purohit P; Barik D; Agasti S; Panda M; Meher BR J Biomol Struct Dyn; 2024 Apr; 42(6):2990-3009. PubMed ID: 37194462 [TBL] [Abstract][Full Text] [Related]
5. Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells. Wu DW; Mao F; Ye Y; Li J; Xu CL; Luo XM; Chen J; Shen X Acta Pharmacol Sin; 2015 Sep; 36(9):1126-36. PubMed ID: 26279156 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity. Takagi Y; Matsui K; Nobori H; Maeda H; Sato A; Kurosu T; Orba Y; Sawa H; Hattori K; Higashino K; Numata Y; Yoshida Y Bioorg Med Chem Lett; 2017 Aug; 27(15):3586-3590. PubMed ID: 28539222 [TBL] [Abstract][Full Text] [Related]
7. Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. Cavina L; Bouma MJ; Gironés D; Feiters MC Molecules; 2024 Aug; 29(17):. PubMed ID: 39274895 [TBL] [Abstract][Full Text] [Related]
8. Targeting the DENV NS2B-NS3 protease with active antiviral phytocompounds: structure-based virtual screening, molecular docking and molecular dynamics simulation studies. Purohit P; Sahoo S; Panda M; Sahoo PS; Meher BR J Mol Model; 2022 Oct; 28(11):365. PubMed ID: 36274116 [TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR and molecular docking studies of peptide-hybrids as dengue virus NS2B/NS3 protease inhibitors. Jitonnom J; Meelua W; Tue-Nguen P; Saparpakorn P; Hannongbua S; Chotpatiwetchkul W Chem Biol Interact; 2024 Jun; 396():111040. PubMed ID: 38735453 [TBL] [Abstract][Full Text] [Related]
10. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side. Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA J Virol; 2017 May; 91(10):. PubMed ID: 28298600 [TBL] [Abstract][Full Text] [Related]
11. Design and docking studies of peptide inhibitors as potential antiviral drugs for dengue virus ns2b/ns3 protease. Velmurugan D; Mythily U; Rao K Protein Pept Lett; 2014; 21(8):815-27. PubMed ID: 23855663 [TBL] [Abstract][Full Text] [Related]
13. Lead Optimization Studies Towards Finding NS2B/NS3 Protease Targetspecific Inhibitors as Potential Anti-dengue Drug-like Compounds. Gurusamy M; Abdul JF Curr Drug Discov Technol; 2019; 16(3):307-314. PubMed ID: 29984660 [TBL] [Abstract][Full Text] [Related]
14. Discovery of antiviral molecules for dengue: In silico search and biological evaluation. Cabarcas-Montalvo M; Maldonado-Rojas W; Montes-Grajales D; Bertel-Sevilla A; Wagner-Döbler I; Sztajer H; Reck M; Flechas-Alarcon M; Ocazionez R; Olivero-Verbel J Eur J Med Chem; 2016 Mar; 110():87-97. PubMed ID: 26807547 [TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors. Luo PH; Zhang XR; Huang L; Yuan L; Zhou XZ; Gao X; Li LS J Recept Signal Transduct Res; 2017 Oct; 37(5):481-492. PubMed ID: 28758854 [TBL] [Abstract][Full Text] [Related]
16. Identification of fused bicyclic derivatives of pyrrolidine and imidazolidinone as dengue virus-2 NS2B-NS3 protease inhibitors. Weng Z; Shao X; Graf D; Wang C; Klein CD; Wang J; Zhou GC Eur J Med Chem; 2017 Jan; 125():751-759. PubMed ID: 27721158 [TBL] [Abstract][Full Text] [Related]
17. Exploring the antiviral inhibitory activity of Niloticin against the NS2B/NS3 protease of Dengue virus (DENV2). Stalin A; Han J; Daniel Reegan A; Ignacimuthu S; Liu S; Yao X; Zou Q Int J Biol Macromol; 2024 Oct; 277(Pt 1):133791. PubMed ID: 38992553 [TBL] [Abstract][Full Text] [Related]
18. Repurposing of investigational cancer drugs: Early phase discovery of dengue virus NS2B/NS3 protease inhibitors. Saleem HN; Kousar S; Jiskani AH; Sohail I; Faisal A; Saeed M Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300292. PubMed ID: 37582646 [TBL] [Abstract][Full Text] [Related]
19. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication. Kouretova J; Hammamy MZ; Epp A; Hardes K; Kallis S; Zhang L; Hilgenfeld R; Bartenschlager R; Steinmetzer T J Enzyme Inhib Med Chem; 2017 Dec; 32(1):712-721. PubMed ID: 28385094 [TBL] [Abstract][Full Text] [Related]
20. Identification of novel and potential inhibitors against the dengue virus NS2B/NS3 protease using virtual screening and biomolecular simulations. Nasir A; Samad A; Ajmal A; Li P; Islam M; Ullah S; Shah M; Bai Q Int J Biol Macromol; 2024 Jun; 272(Pt 1):132855. PubMed ID: 38834129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]